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The influence of caspofungin on polymorphonuclear leukocyte (PMN) phagocytosis and intracellular killing
of Candida albicans was investigated. Caspofungin, at all of the concentrations tested (2, 3.2, and 8 g/ml),
significantly increased intracellular killing by PMNs through its direct action on both yeast cells and PMNs,
indicating the potential ability of caspofungin to synergize with phagocytes for candidal killing. Caspofungin
may therefore constitute an effective therapeutic option for the treatment of invasive fungal infections,
including those refractory to conventional treatment with azole agents.
Echinocandins, such as caspofungin, are new drugs that
broaden the available therapeutic arsenal for invasive fungal
infection (IFI) treatment (6, 7, 11). Caspofungin displays fa-
vorable pharmacodynamic and pharmacokinetic characteris-
tics and has an excellent toxicological profile and antifungal
activity against Candida spp., Aspergillus spp., Histoplasma
spp., Blastomyces spp., and Coccidioides spp. (3, 7, 11, 12, 15).
As the current trend in therapy requires drugs with high in vitro
activity associated with the capacity to potentiate host defense
mechanisms, especially in immunocompromised hosts (2, 19),
the interaction of caspofungin with human polymorphonuclear
leukocytes (PMNs) was evaluated, focusing on both the phago-
cytosis and intracellular killing of Candida albicans.
(This study was presented in part at the Congress of the
Italian Society of Pharmaceutical Microbiology, Turin, Italy, 20
to 22 June 2008.)
A clinical C. albicans strain isolated from blood and identi-
fied by biochemical methods was subcultured on Sabouraud
dextrose agar (Oxoid S.p.A., Milan, Italy) to ensure viability
and purity. Yeast cultures consisted entirely of blastoconidia
and had a slight tendency to differentiate into pseudohyphae
during the course of the experiments.
Caspofungin acetate (Merck Sharp & Dohme Ltd., Hoddes-
don, United Kingdom) was dissolved in pyrogen-free water
and stored at 20°C. Antifungal susceptibility testing was per-
formed with an inoculum of 103 CFU/ml, in accordance with
CLSI M27-A3 (4), and an inoculum of 106 CFU/ml was used to
perform tests with phagocytes.
PMNs were separated from lithium heparinized venous
blood using Ficoll-Paque (Pharmacia S.p.A., Milan, Italy) and
adjusted to 106 cells/ml in RPMI 1640 medium (Gibco Labo-
ratories, Grand Island, NY) (1, 5). Viability, determined by
trypan blue exclusion, was greater than 95%.
The effect of caspofungin on the phagocytosis of radiola-
beled C. albicans ([3H]uracil [specific activity, 1,270 GBq/
mmol; NEN Life Science Products, Milan, Italy]) by PMNs was
investigated by incubating the yeast cells (106 invasive fungal
cells/ml) and PMNs (106 cells/ml) at 37°C in a shaking water
bath in the presence of 2 g/ml (MIC), 3.2 g/ml, or 8 g/ml
caspofungin; the last two concentrations were within the range
achieved clinically (8, 9). Caspofungin-free controls were in-
cluded. After 30, 60, or 90 min, phagocytosis was assessed (18,
19). PMNs were centrifuged twice at 200  g for 5 min to
remove free blastoconidia and suspended in sterile water for 5
min; 100-l samples were placed in scintillation fluid (Atom-
light; NEN) and counted by spectrophotometry. Radioactivity
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TABLE 1. Effect of caspofungin on intracellular killing of C. albicans by human PMNs
Time (min)
Mean SI  SEM (% of initial fungal population killed by PMNs in absence or presence of caspofungin)
Control 2 g/ml (MIC) 3.2 g/mla 8 g/mla
30 1.54  0.03 (46) 1.29  0.07 (71)b 1.28  0.09 (72)b 1.26  0.07 (74)b
60 1.53  0.02 (47) 1.28  0.11 (72)b 1.25  0.09 (75)b 1.17  0.06 (83)b
90 1.52  0.03 (48) 1.25  0.07 (75)b 1.14  0.04 (86)b 1.17  0.11 (83)b
a Concentration within the range achieved clinically.
b Significantly different from the control (P  0.01).
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was expressed as counts per minute (cpm) per sample. The
percentage of phagocytosis at a given sampling time was cal-
culated as follows: % phagocytosis  [(cpm in PMN pellet)/
(cpm in total fungal pellet)]100 (18, 19). Intracellular killing
was investigated by incubating yeast cells and PMNs (1:1 ratio)
for 30 min to allow phagocytosis to proceed. The PMN-yeast
cell mixtures were centrifuged at 200 g for 5 min and washed
to remove extracellular blastoconidia. An aliquot of PMNs was
lysed by adding sterile water, and intracellular viable yeast cell
counting was performed (time zero). PMNs were incubated
further with 2, 3.2, or 8 g/ml caspofungin, and at time x (30,
60, and 90 min), the viable counts were measured in the same
way. Killing values were expressed as a survival index (SI),
which was calculated by adding the number of surviving yeast
cells at time zero to the number of survivors at time x and
dividing by the number of survivors at time zero. According to
this formula, if fungal killing was 100% effective, the SI would
be 1 (18, 19). To differentiate between any separate effect of
caspofungin on the yeast cells and PMNs, the experiments
were conducted after the exposure of each of them to 2, 3.2, or
8 g/ml caspofungin for 1 h, before they were incubated to-
gether (16, 17). After the withdrawal of caspofungin, preex-
posed blastoconidia were added to PMNs and blastoconidia
were added to preexposed PMNs. Drug-free controls were
included. Intracellular killing was determined as described
above. Results were expressed as the mean  the standard
error of the mean (SEM) of 10 separate experiments, each
performed in quadruplicate. Statistical evaluation of the dif-
ferences between test and control results was performed by
Tukey’s test.
The majority of systemic antifungal drugs do not signifi-
cantly influence the phagocytic activity of PMNs against Can-
dida spp. (8, 13, 14). We reported that fluconazole enhances
the in vitro killing activity of phagocytes against C. albicans,
without improving phagocytosis (18, 19). We observed a sim-
ilar pattern for caspofungin (data not shown), probably owing
to the altered expression of surface molecules that link to
cleavage products of complement (13). On the contrary, under
the same experimental conditions, caspofungin showed a
marked effect on the survival of blastoconidia, with SI values
that ranged from 1.25 to 1.29, 1.14 to 1.28, and 1.17 to 1.26 for
the three drug concentrations tested, compared with those for
the caspofungin-free controls (P  0.01; Table 1).
To determine whether the increased killing activity of caspo-
fungin was due to its direct action on C. albicans or its action
on phagocytes, yeast cells and PMNs were separately exposed
to 2, 3.2, or 8 g/ml caspofungin for 1 h prior to killing tests.
Yeast cells pretreated with caspofungin at the MIC were killed
more efficiently by the PMNs than were untreated yeast cells:
SI  1.31, 1.31, and 1.18 versus 1.54, 1.53, and 1.52 (P  0.01;
Table 2). Yeast killing was stimulated to about the same de-
gree (3.2 g/ml) or to a slightly lower degree (8 g/ml) than
that observed with caspofungin at the MIC but significantly
more than that seen in the controls (P  0.01; Table 2). This
finding could be correlated with caspofungin’s ability to un-
mask a virulence factor in the inner -glucan cell wall layer,
making intracellular yeast cells more susceptible to PMN lytic
mechanisms (10, 21).
Pretreatment of PMNs with caspofungin at the MIC resulted
in a significant enhancement of intracellular killing throughout
the observation period compared with that in controls (SI 
1.28, 1.24, and 1.18 versus 1.54, 1.53, and 1.52; P  0.01; Table
2). Similarly, PMNs pretreated with caspofungin at supra-
MICs (3.2 and 8 g/ml) were highly effective in clearing viable
blastoconidia, compared with controls (SI  1.31, 1.16, and
1.09 and 1.21, 1.18, and 1.06, respectively; P  0.01; Table 2),
thus providing indirect evidence of the drug’s ability to enter
phagocytes and remain available in a form that is biologically
active against proliferating yeast cells. Our results differ some-
what from those obtained by van Asbeck et al. with C. parap-
silosis, showing impairment of the innate immune mechanisms;
however, these data are difficult to compare because of the
differences in the experimental designs and methods used (20).
In conclusion, our findings suggest that caspofungin, at the
MIC and at concentrations that are achieved clinically during
antifungal therapy, displays a positive interaction with PMNs
through its direct action on both yeast cells and PMNs. Caspo-
fungin may therefore constitute an effective therapeutic option
for the treatment of IFIs, including those refractory to conven-
tional treatment with azole agents.
This work was supported by grants from the Italian MUR (2008) and
from Piedmont Region, Ricerca Scientifica Finalizzata 2008 bis.
We thank Eugene Y. Cheung for helpful English revision of the
manuscript.
REFERENCES
1. Banche, G., V. Allizond, F. Giacchino, N. Mandras, J. Roana, F. Bonello, P.
Belardi, V. Tullio, C. Merlino, N. Carlone, and A. M. Cuffini. 2006. Effect of
dialysis membrane biocompatibility on polymorphonuclear granulocyte ac-
tivity in dialysis patients. Nephrol. Dial. Transplant. 21:3532–3538.
2. Ben-Ami, R., R. E. Lewis, and D. P. Kontoyiannis. 2008. Immunocompro-
mised hosts: immunopharmacology of modern antifungals. Clin. Infect. Dis.
47:226–235.
3. Chiller, T., K. Farrokhshad, E. Brummer, and D. A. Stevens. 2001. The
interaction of human monocytes, monocyte-derived macrophages, and poly-
morphonuclear neutrophils with caspofungin (MK-0991), an echinocandin,
for antifungal activity against Aspergillus fumigatus. Diagn. Microbiol. Infect.
Dis. 39:99–103.
4. Clinical and Laboratory Standards Institute. 2008. Reference method for
TABLE 2. Effect of preexposure of C. albicans or human PMNs to caspofungin for 1 h on PMN intracellular killing
Time (min) Control
Mean SI  SEM (% of initial fungal population killed by PMNs in absence or presence of caspofungin)
Preexposure of C. albicans Preexposure of human PMNs
2 g/ml (MIC) 3.2 g/mla 8 g/mla 2 g/ml (MIC) 3.2 g/mla 8 g/mla
30 1.54  0.03 (46) 1.31  0.1 (69)b 1.37  0.10 (63)b 1.37  0.04 (63)b 1.28  0.12 (72)b 1.31  0.07 (69)b 1.21  0.16 (79)b
60 1.53  0.02 (47) 1.31  0.06 (69)b 1.26  0.06 (74)b 1.34  0.04 (66)b 1.24  0.06 (76)b 1.16  0.12 (84)b 1.18  0.01 (82)b
90 1.52  0.03 (48) 1.18  0.05 (82)b 1.22  0.09 (78)b 1.28  0.04 (72)b 1.18  0.07 (82)b 1.09  0.01 (91)b 1.06  0.04 (94)b
a Concentration within the range achieved clinically.
b Significantly different from the controls (P  0.01).
VOL. 54, 2010 CASPOFUNGIN INFLUENCE ON PMNs AGAINST CANDIDA ALBICANS 3965
broth dilution antifungal susceptibility testing of yeasts; third edition. Ap-
proved standard M27-A3. Clinical and Laboratory Standards Institute,
Wayne, PA.
5. Cuffini, A. M., V. Tullio, F. Giacchino, N. Mandras, D. Scalas, P. Belardi, C.
Merlino, and N. A. Carlone. 2001. Impact of co-amoxiclav on polymorpho-
nuclear granulocytes from chronic hemodialysis patients. Am. J. Kidney Dis.
37:1253–1259.
6. Denning, D. W., and W. W. Hope. 2010. Therapy for fungal diseases: oppor-
tunities and priorities. Trends Microbiol. 18:195–204.
7. Deresinski, S. C., and D. A. Stevens. 2003. Caspofungin. Clin. Infect. Dis.
36:1445–1457.
8. Frank, U., M. Greiner, I. Engels, and F. D. Daschner. 2004. Effects of
caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis,
oxidative burst and killing of Candida albicans by human phagocytes. Eur.
J. Clin. Microbiol. Infect. Dis. 23:729–731.
9. Groll, A. H., and T. J. Walsh. 2001. Caspofungin: pharmacology, safety and
therapeutic potential in superficial and invasive fungal infections. Expert
Opin. Investig. Drugs 10:1545–1558.
10. Lamaris, G. A., R. E. Lewis, G. Chamilos, G. S. May, A. Safdar, T. J. Walsh,
I. I. Raad, and D. P. Kontoyiannis. 2008. Caspofungin-mediated -glucan
unmasking and enhancement of human polymorphonuclear neutrophil ac-
tivity against Aspergillus and non-Aspergillus hyphae. J. Infect. Dis. 198:186–
192.
11. Letscher-Bru, V., and R. Herbrecht. 2003. Caspofungin: the first represen-
tative of a new antifungal class. J. Antimicrob. Chemother. 51:513–521.
12. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella,
A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A.
Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W.
Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R.
Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-
Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W.
Warnock. 2004. Interlaboratory comparison of results of susceptibility test-
ing with caspofungin against Candida and Aspergillus species. J. Clin. Micro-
biol. 42:3475–3482.
13. Richardson, M. D., G. Scott, and G. S. Shankland. 1992. Effect of cilofungin
on phagocytosis and intracellular killing of Candida albicans by human neu-
trophils. Eur. J. Clin. Microbiol. Infect. Dis. 11:22–26.
14. Roilides, E., T. J. Walsh, M. Rubin, D. Venzon, and P. A. Pizzo. 1990. Effects
of antifungal agents on the function of human neutrophils in vitro. Antimi-
crob. Agents Chemother. 34:196–201.
15. Stone, J. A., S. D. Holland, P. J. Wickersham, A. Sterrett, M. Schwartz, C.
Bonfiglio, M. Hesney, G. A. Winchell, P. J. Deutsch, H. Greenberg, T. L.
Hunt, and S. A. Waldman. 2002. Single- and multiple-dose pharmacokinetics
of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739–745.
16. Tullio, V., A. Cuffini, N. Mandras, J. Roana, G. Banche, D. Ungheri, and N.
Carlone. 2004. Influence of thiamphenicol on the primary functions of hu-
man polymorphonuclear leucocytes against Streptococcus pyogenes. Int. J.
Antimicrob. Agents 24:381–385.
17. Tullio, V., A. M. Cuffini, G. Banche, N. Mandras, V. Allizond, J. Roana, F.
Giacchino, F. Bonello, D. Ungheri, and N. A. Carlone. 2008. Role of fosfo-
mycin tromethamine in modulating non-specific defence mechanisms in
chronic uremic patients towards ESBL-producing Escherichia coli. Int. J. Im-
munopathol. Pharmacol. 21:153–160.
18. Tullio, V., A. M. Cuffini, C. De Leo, F. Perrone, and N. A. Carlone. 1996.
Interaction of Candida albicans, macrophages and fluconazole: in vitro and ex
vivo observations. J. Chemother. 8:438–444.
19. Tullio, V., A. M. Cuffini, F. Giacchino, N. Mandras, J. Roana, L. Comune, C.
Merlino, and N. A. Carlone. 2003. Combined action of fluconazole and
PMNs from uremic patients in clearing intracellular Candida albicans.
J. Chemother. 15:301–303.
20. van Asbeck, E. C., A. I. Hoepelman, J. Scharringa, and J. Verhoef. 2009. The
echinocandin caspofungin impairs the innate immune mechanism against
Candida parapsilosis. Int. J. Antimicrob. Agents 33:21–26.
21. Wheeler, R. T., and G. R. Fink. 2006. A drug-sensitive genetic network masks
fungi from the immune system. PLoS Pathog. 2:e35.
3966 TULLIO ET AL. ANTIMICROB. AGENTS CHEMOTHER.
